Genademy Genademy.
Regulatory Intelligence

State-by-State Regulatory Heat Map

Regenerative medicine regulation varies by state. This living tracker maps the permissiveness landscape for exosomes, peptides, stem cells, and biologics across all 50 states plus DC. Updated with the latest enforcement actions and legislative changes.

Federal Framework

The FDA classifies exosomes and most regenerative medicine products as biologics under PHS Act Section 351 and the FD&C Act. No exosome product has FDA approval for any therapeutic use. Full premarket approval (BLA or IND) is required before commercial distribution.

  • Enforcement trend: Accelerating. 13+ FDA warning letters to exosome/stem cell companies since December 2024, including inspection-based CGMP charges as of August 2026.
  • Key guidance: 21 CFR 1271 (HCT/P framework). Exosomes generally do NOT qualify for the 361 minimal-manipulation exception.
  • Consumer alert: FDA issued a Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes (updated March 2026).
  • PCAC July 2026: Bulks List vote recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon; DSIP/emideltide rejected 6-7.
Permissive
Regulated
Restrictive
Unregulated (no specific statute)

Methodology: Compiled from state statutes, FDA enforcement actions, medical board publications, and legal analysis. Each state is rated on a permissiveness scale from 1 (restrictive) to 4 (most permissive). This is journalism and market intelligence, not legal advice. State laws govern provider conduct, consent, and disclosure. They do not make products FDA-approved. Always verify your scope of practice with your licensing board before offering any therapy.

Genademy provides professional education for licensed healthcare practitioners. Course content is for educational purposes and does not constitute medical advice, treatment recommendations, or claims regarding any product. Products referenced may be investigational or not FDA-approved for the uses discussed. Practitioners are responsible for verifying their own scope of practice and applicable regulations.